29 documents showing 1–29

Aug 18, 2025

Spruce Point Capital

iRhythm Technologies, Inc. IRTC

Spruce Point argues iRhythm hid FDA-flagged Zio AT defects that killed patients and faces a DOJ cover-up probe; commoditized tech and an overstated asymptomatic market imply 40-70% downside.

N4 V3

May 03, 2025

White Diamond Research

Pulse Biosciences PLSE

PLSE's pivot to benign thyroid ablation repeats its failed dermatology playbook — tiny market, weak clinical data, revolving-door CEOs — and will trigger another stock collapse.

N3 V3

Jan 16, 2025

Spruce Point Capital

PROCEPT BioRobotics Corporation PRCT

Procept trades at 14x revenue on a false 'all-prostates' TAM; Spruce Point sees channel-stuffing via DSOs at 130 days, no procedure growth, and 30-60% downside to $29-$54.

N4 V3

Jan 08, 2025

Trian Partners

Solventum Corporation SOLV

Solventum's post-spin performance collapse is nearly worst-in-class; restoring 3M-era 3-4% growth and 26% margins plus simplifying the portfolio can double shares to $140 by 2027.

N4 V3

Oct 01, 2024

Starboard Value

Pfizer Inc. PFE

Pfizer destroyed $20-60bn of value since 2019 despite a $40bn COVID windfall; Starboard wants the board to hold Bourla accountable for peer-median R&D/M&A returns.

N5 V4

Oct 01, 2024

Starboard Value

Pfizer Inc. PFE

Pfizer squandered its $40bn COVID windfall on overpriced M&A while delivering almost none of the 15 promised blockbusters; the Board must hold management accountable.

N5 V4

Oct 01, 2023

Starboard Value

Fortrea Holdings Inc. FTRE

Fortrea, LabCorp's spun-out CRO, earns 9% EBITDA margins versus 18% peers; CEO Tom Pike's IQVIA playbook implies $47-$72 per share, 60-144% upside at normalized margins.

N4 V3

Jul 13, 2023

Spruce Point Capital

Hims & Hers Health, Inc. HIMS

HIMS is an overvalued, commoditized ED/hair-loss e-commerce business masquerading as healthcare, with CPoM regulatory risk and new OTC Eroxon competition driving 25-40% downside to $5.20-$6.50.

N4 V3

Apr 06, 2022

Spruce Point Capital

Stryker Corp. SYK

Spruce Point exposes Stryker's FCPA-tainted accounting, failing acquisition roll-up and margin squeeze under CEO Lobo — Strong Sell with 35%-75% downside to $67-$174.50.

N4 V3

Oct 25, 2021

Spruce Point Capital

Heska Corporation HSKA

Heska is a low-growth animal-health distributor — not the innovator management claims — masquerading at a 9x-sales SaaS multiple; Spruce Point sees 50-60% downside to $90-$115.

N4 V3

Sep 01, 2020

Kerrisdale Capital

AtriCure, Inc. ATRC

AtriCure's 7.5x revenue valuation assumes stand-alone Convergent succeeds, but electrophysiologists won't refer, and PFA plus real-time mapping will obsolete surgical ablation.

N4 V3

Apr 09, 2020

Spruce Point Capital

Align Technology, Inc. ALGN

Align's Invisalign moat is eroding as FDA-approved third-party 3D-printing labs and 3M Clarity undercut prices by 50-65%, driving 40-55% downside to $80-$115.

N4 V3

Jan 15, 2020

Spruce Point Capital

LHC Group, Inc. LHCG

LHCG's 20.6x EBITDA multiple rests on phantom organic growth — excluding the failing Almost Family acquisition inflates growth ~500 bps, masking sub-2% reality and 35-65% downside to $60-$90.

N4 V4

Oct 29, 2019

Spruce Point Capital

Hill-Rom Holdings, Inc. HRC

Hill-Rom is a low-quality medical roll-up whose plateauing new products, exhausted margin expansion and aggressive accounting point to a 25-55% drop to $45-$75 per share.

N5 V4

Sep 25, 2019

Spruce Point Capital

Premier, Inc. PINC

Premier's earnings are artificially inflated by expiring pre-IPO shareback contracts; as member hospitals renegotiate at market rates, EBITDA halves and shares fall 55-75% to $8-$15.

N5 V3

Jul 31, 2019

Spruce Point Capital

Penumbra, Inc. PEN

Penumbra is a commoditized single-product 510(k) company whose aspiration-catheter franchise is collapsing to deep-pocketed bundlers; Spruce Point sees 40-55% downside to $85-110 per share.

N4 V3

Mar 21, 2019

Spruce Point Capital

Dexcom, Inc. DXCM

Dexcom's blow-out growth is a sugar high — driven by hidden price hikes and sensor stockpiling — and Abbott's cheap Libre 2 will commoditize CGMs, taking DXCM down 45-60% to $65-$85.

N4 V3

Feb 25, 2019

Muddy Waters

Inogen INGN

INGN's growth narrative rests on an inflated $3-4B TAM that Medicare data contradicts; under a realistic 1.3M-user market, peak unit sales arrive this year or next.

N4 V1

Feb 15, 2019

Citron Research

Inogen INGN

Inogen's growth is built on a reseller network that lies to elderly customers about Medicare coverage to force cash sales — competition and oversight will collapse margins to a $46 stock.

N4 V2

Feb 08, 2019

Muddy Waters

Inogen, Inc. INGN

Inogen's growth story rests on a fabricated TAM sourced from a plagiarism-riddled WinterGreen report; real market is shrinking, peak sales arrive 2019-2020, target $46 (-67%).

N5 V2

Sep 26, 2018

Spruce Point Capital

Henry Schein, Inc. HSIC

HSIC's soon-to-spin Vets First Corp is growing far faster than the Street thinks — proprietary data shows 75% install-base growth, driving a $106-126 SOTP target vs. $84 today.

N4 V3

Nov 01, 2017

Kerrisdale Capital

Adamas Pharmaceuticals, Inc. ADMS

Kerrisdale is long ADMS: Gocovri, the only FDA-approved drug for levodopa-induced dyskinesia, plus an MS and Vimpat XR pipeline, is worth over $100/share versus ~$25 today.

N4 V3

Sep 12, 2016

Starboard Value

Perrigo Company plc PRGO

Perrigo lost half its value after rejecting Mylan's $205 bid; divesting Rx and Tysabri royalty, fixing BCH margins, and restoring credibility can re-rate the stock to consumer-staples peers.

N4 V3

Oct 30, 2015

Pershing Square

Valeant Pharmaceuticals International VRX

Citron's 'next Enron' attack on Valeant is a 1963 AmEx Salad Oil rerun — Philidor is ~7% of sales, the franchise is intact, and VRX at 7x cash EPS offers 60-215% upside.

N5 V3

Oct 30, 2015

Pershing Square

Valeant Pharmaceuticals International VRX

Citron's 'next Enron' attack on Valeant overstates the risk: Philidor is only ~6% of sales, and even written off, VRX trades at ~8x 2016 cash EPS with 135%+ long-term upside.

N4 V3

May 04, 2015

Pershing Square

Valeant Pharmaceuticals International VRX

Valeant is mis-valued on a traditional earnings multiple; crediting its Pearson-led Platform Value — like Jarden or Danaher — unlocks $330+/share, ~48% upside from $223.

N5 V4

May 04, 2015

Pershing Square

Valeant Pharmaceuticals International VRX

Valeant is a platform compounder that traditional P/E undervalues; SOTP plus credit for ongoing M&A implies $330+/share vs $223 today, with up to $618 by 2020.

N5 V3

May 05, 2014

Greenlight Capital

athenahealth ATHN

athenahealth is the poster child of the cloud 'bubble basket' — strip Morgan Stanley's fantasy margin and revenue-per-doctor assumptions and the stock falls 80%+ toward a $50 adjusted DCF.

N5 V2

Apr 22, 2014

Pershing Square

Allergan, Inc. AGN

Allergan shareholders should accept Valeant's bid: Valeant is an 'Outsider'-style acquirer (25x TSR under Pearson) whose lean R&D and platform M&A will compound Val-gan's value far beyond Allergan standalone.

N5 V3